661 related articles for article (PubMed ID: 38673943)
1. The Contribution of Type 2 Diabetes to Parkinson's Disease Aetiology.
Ribarič S
Int J Mol Sci; 2024 Apr; 25(8):. PubMed ID: 38673943
[TBL] [Abstract][Full Text] [Related]
2. Faster disease progression in Parkinson's disease with type 2 diabetes is not associated with increased α-synuclein, tau, amyloid-β or vascular pathology.
de Pablo-Fernández E; Courtney R; Rockliffe A; Gentleman S; Holton JL; Warner TT
Neuropathol Appl Neurobiol; 2021 Dec; 47(7):1080-1091. PubMed ID: 33969516
[TBL] [Abstract][Full Text] [Related]
3. Synergistic Effects of Milk-Derived Exosomes and Galactose on
Melnik BC
Int J Mol Sci; 2021 Jan; 22(3):. PubMed ID: 33494388
[TBL] [Abstract][Full Text] [Related]
4. Insulin Resistance Promotes Parkinson's Disease through Aberrant Expression of α-Synuclein, Mitochondrial Dysfunction, and Deregulation of the Polo-Like Kinase 2 Signaling.
Hong CT; Chen KY; Wang W; Chiu JY; Wu D; Chao TY; Hu CJ; Chau KD; Bamodu OA
Cells; 2020 Mar; 9(3):. PubMed ID: 32192190
[No Abstract] [Full Text] [Related]
5. Type 2 Diabetes and Parkinson's Disease: A Focused Review of Current Concepts.
Cullinane PW; de Pablo Fernandez E; König A; Outeiro TF; Jaunmuktane Z; Warner TT
Mov Disord; 2023 Feb; 38(2):162-177. PubMed ID: 36567671
[TBL] [Abstract][Full Text] [Related]
6. Type 2 Diabetes (T2DM) and Parkinson's Disease (PD): a Mechanistic Approach.
Sabari SS; Balasubramani K; Iyer M; Sureshbabu HW; Venkatesan D; Gopalakrishnan AV; Narayanaswamy A; Senthil Kumar N; Vellingiri B
Mol Neurobiol; 2023 Aug; 60(8):4547-4573. PubMed ID: 37118323
[TBL] [Abstract][Full Text] [Related]
7. Toll-like receptor 2 is increased in neurons in Parkinson's disease brain and may contribute to alpha-synuclein pathology.
Dzamko N; Gysbers A; Perera G; Bahar A; Shankar A; Gao J; Fu Y; Halliday GM
Acta Neuropathol; 2017 Feb; 133(2):303-319. PubMed ID: 27888296
[TBL] [Abstract][Full Text] [Related]
8. Long-term hyperglycemia aggravates α-synuclein aggregation and dopaminergic neuronal loss in a Parkinson's disease mouse model.
Lv YQ; Yuan L; Sun Y; Dou HW; Su JH; Hou ZP; Li JY; Li W
Transl Neurodegener; 2022 Mar; 11(1):14. PubMed ID: 35255986
[TBL] [Abstract][Full Text] [Related]
9. NF-κB/NLRP3 inflammasome axis and risk of Parkinson's disease in Type 2 diabetes mellitus: A narrative review and new perspective.
Alrouji M; Al-Kuraishy HM; Al-Gareeb AI; Alexiou A; Papadakis M; Jabir MS; Saad HM; Batiha GE
J Cell Mol Med; 2023 Jul; 27(13):1775-1789. PubMed ID: 37210624
[TBL] [Abstract][Full Text] [Related]
10. The Association Between Type 2 Diabetes Mellitus and Parkinson's Disease.
Cheong JLY; de Pablo-Fernandez E; Foltynie T; Noyce AJ
J Parkinsons Dis; 2020; 10(3):775-789. PubMed ID: 32333549
[TBL] [Abstract][Full Text] [Related]
11. Gut microbiome, short-chain fatty acids, alpha-synuclein, neuroinflammation, and ROS/RNS: Relevance to Parkinson's disease and therapeutic implications.
Kalyanaraman B; Cheng G; Hardy M
Redox Biol; 2024 May; 71():103092. PubMed ID: 38377788
[TBL] [Abstract][Full Text] [Related]
12. Interaction of amyloidogenic proteins in pancreatic β cells from subjects with synucleinopathies.
Martinez-Valbuena I; Amat-Villegas I; Valenti-Azcarate R; Carmona-Abellan MDM; Marcilla I; Tuñon MT; Luquin MR
Acta Neuropathol; 2018 Jun; 135(6):877-886. PubMed ID: 29536165
[TBL] [Abstract][Full Text] [Related]
13. Neuroinflammation and protein pathology in Parkinson's disease dementia.
Kouli A; Camacho M; Allinson K; Williams-Gray CH
Acta Neuropathol Commun; 2020 Dec; 8(1):211. PubMed ID: 33272323
[TBL] [Abstract][Full Text] [Related]
14. Direct visualization of alpha-synuclein oligomers reveals previously undetected pathology in Parkinson's disease brain.
Roberts RF; Wade-Martins R; Alegre-Abarrategui J
Brain; 2015 Jun; 138(Pt 6):1642-57. PubMed ID: 25732184
[TBL] [Abstract][Full Text] [Related]
15. A newly discovered neurotoxin ADTIQ associated with hyperglycemia and Parkinson's disease.
Xie B; Lin F; Ullah K; Peng L; Ding W; Dai R; Qing H; Deng Y
Biochem Biophys Res Commun; 2015 Apr; 459(3):361-6. PubMed ID: 25744031
[TBL] [Abstract][Full Text] [Related]
16. Diabetes Mellitus as a Risk Factor for Parkinson's Disease: a Molecular Point of View.
Biosa A; Outeiro TF; Bubacco L; Bisaglia M
Mol Neurobiol; 2018 Nov; 55(11):8754-8763. PubMed ID: 29594935
[TBL] [Abstract][Full Text] [Related]
17. Peripheral inflammation exacerbates α-synuclein toxicity and neuropathology in Parkinson's models.
La Vitola P; Balducci C; Baroni M; Artioli L; Santamaria G; Castiglioni M; Cerovic M; Colombo L; Caldinelli L; Pollegioni L; Forloni G
Neuropathol Appl Neurobiol; 2021 Feb; 47(1):43-60. PubMed ID: 32696999
[TBL] [Abstract][Full Text] [Related]
18. Pathomechanism Characterization and Potential Therapeutics Identification for Parkinson's Disease Targeting Neuroinflammation.
Chen CM; Yen CY; Chen WL; Lin CH; Wu YR; Chang KH; Lee-Chen GJ
Int J Mol Sci; 2021 Jan; 22(3):. PubMed ID: 33494411
[TBL] [Abstract][Full Text] [Related]
19. The Role of α-Synuclein Oligomers in Parkinson's Disease.
Du XY; Xie XX; Liu RT
Int J Mol Sci; 2020 Nov; 21(22):. PubMed ID: 33212758
[TBL] [Abstract][Full Text] [Related]
20. [Parkinson's disease and type 2 diabetes mellitus: interrelation of pathogenetic mechanisms and general therapeutic approaches].
Troshneva AY; Ametov AS
Zh Nevrol Psikhiatr Im S S Korsakova; 2022; 122(11. Vyp. 2):12-18. PubMed ID: 36412150
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
